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ity for stage I NSCLC. Luck of evidence of PBT for locally advanced 
NSCLC is disappointing (several facilities are conducting clinical 
trials), the greatest opportunity for improved outcome in patients with 
locally advanced NSCLC is ﬁrmly believed the combination of PBT 
with higher doses that possible with photons today, and concurrent 
chemotherapy.
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International early lung cancer action program
Henschke, Claudia I. 
Cornell University Medical College, New York, NY, USA
Since CT screening for lung cancer began in 1993 in the context of the 
Early Lung Cancer Action Project (ELCAP) (1, 2), it has expanded 
into an international collaboration called I-ELCAP (3) with over 
35,000 people have undergone baseline and annual repeat screening 
following the I-ELCAP regimen of screening. At baseline, it was been 
found that 15% had a positive result of the initial CT test and at annual 
repeat screening, 6% had a positive result (4). The updated deﬁnition 
of a positive result of the initial CT test at baseline (5) is an updated 
version of that originally used in original ELCAP: at least 1 solid or 
part-solid noncalciﬁed nodule 5 mm or more in diameter, and/or at 
least 1 nonsolid noncalciﬁed nodule 8 mm or more in diameter. When 
noncalciﬁed nodules were identiﬁed but all of them were too small to 
imply a positive result, the result was viewed as ‘semi-positive’ in the 
sense of calling for repeat CT one year later. For repeat screening, the 
deﬁnition of positive result of the initial CT test remained the same as 
the original ELCAP: any newly identiﬁed noncalciﬁed nodule that evi-
dently had grown since the prior screen, regardless of size or anything 
else, except that deﬁnition of growth was updated to account for nodule 
consistency: alternatives to any enlargement, identiﬁed visually by the 
radiologist, of the entire nodule included growth of the solid compo-
nent of a part-solid nodule and development of a solid component in a 
previously nonsolid nodule.
The I-ELCAP regimen provides recommendations for the work-up, but 
the actual decision is left to each screenee and his/her referring physi-
cian. In the I-ELCAP approach, this does not compromise the validity 
of the study as long as actions, results of the subsequent tests, and inter-
ventions are documented for each screenee. Adherence to the regimen, 
however, does affect the performance of the regimen as it determines 
the frequency of unnecessary biopsy or surgery and the timeliness of 
the diagnosis which ultimately determines the stage and resectability of 
the screen-diagnosed lung cancer. Thus, for adequate performance of 
any screening regimen, adherence to it by the screenees and their refer-
ring physicians is important. 
Following the I-ELCAP protocol, over 90% of the recommended 
biopsies resulted in a diagnosis of malignancy (4). Thus, the recom-
mendations turned out to be quite successful as to avoidance of undue 
invasive procedures, complications, and cost. None of the biopsies 
performed without the regimen’s recommendation resulted in diagnosis 
of lung cancer. Detailed pathologic review of the specimens showed all 
were genuine lung cancers and showed the differences between cancers 
diagnosed in the baseline round from those diagnosed in the repeat 
rounds (6).
These screenings have resulted in 85% of the screen-diagnoses as being 
of clinical Stage I diagnosis (4). We also found a signiﬁcant decrease in 
the frequency of Stage I with increasing tumor diameter (7). The per-
centages of Stage I cases were much higher than those reported from 
the SEER registry data, although the trend was evident in the SEER 
data as well (8). Long-term follow-up of early diagnoses in the SEER 
was also addressed (9, 10). 
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Long-term follow-up of these screen-diagnosed cases showed that 
the 10-year Kaplan-Meier survival rates for all cases, regardless of 
stage and treatment, was 80%. If the cancer was in clinical Stage I and 
promptly resected, the 10-year rate was 92% (11). Concerns expressed 
about leadtime, length, and overdiagnosis bias were addressed in our 
responses to the letters to the Editor (12). We do have a comparison 
group, but at the time of treatment where it is appropriate and our com-
parisons do not have lead time bias (12).
Bach et al. (13) used a model to predict deaths in from lung cancer and 
applied it to 3 small studies of CT screening in asymptomatic people 
at risk of lung cancer and found that there was no reduction in deaths 
by screening. They did not distinguish between baseline and annual 
screening. Most importantly, they included more than 5 deaths in symp-
tomatic people and at least another 6 who did have any per protocol 
imaging and biopsy. Had even 5 of these inadmissible enrollees been 
excluded, the conclusions would have been reversed as there would 
have been a statistically signiﬁcant reduction in deaths. Thus, Bach 
et al.’s ﬁndings when correctly presented conﬁrmed the ﬁndings of 
I-ELCAP.
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Bronchioloalveolar carcinoma
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Bronchioloalveolar carcinoma (BAC) is a malignant epithelial tumor 
of peripheral airways that spreads along the alveolar surfaces without 
destroying underlying alveolar structures in a pattern that is referred of 
growth that is referred to as “lepidic”. BAC is relatively recent concept 
with the term “bronchioloalveolar carcinoma” only introduced in 1960 
as “...well-differentiated adenocarcinomas primary in the periphery 
of the lung beyond a grossly recognizable bronchus, with a tendency 
to spread chieﬂy within the conﬁnes of the lung by aerogenous and 
lymphatic routes...”(1). The concept has evolved largely on the basis of 
data accumulated through Japanese studies indicating that small tumors 
(<2 cm, size often detected by CT screening) BAC without evidence 
of invasion have a uniformly excellent prognosis(2). On the basis of 
these data BAC was redeﬁned by the WHO as an in situ lesion without 
evidence of stromal invasion. This reclassiﬁcation been criticized for 
several reasons:
1. The data on which it was based was derived from careful studies 
using processing methods that are not the standard of practice in 
Western countries. The Japanese data may not be reproducible in 
less rigorous non-research environments in the West.
2. It is now known that the molecular proﬁle of lung cancer in Japan is 
different that in the 
West and more frequently includes EGFR mutation and less frequent 
Ki-ras mutation suggesting that tumors in Japan may be biologically 
different than those in the West.
3. The importance of the distinction between mucinous and non-muci-
nous tumors and relationship between classical BAC and other more 
recently described forms of intra-alveolar growth patterns such as 
papillary and micropapillary is only now being appreciated.
These issues have special relevance to ongoing CT trials and their 
relevance to biological modeling and clinical management will be 
discussed.
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Background
The practice of VATS lobectomy for primary surgical therapy of early 
stage non-small cell lung cancer (NSCLC) is increasing, but has not be-
come widespread practice despite indications that the procedure is safe 
and oncologically acceptable in patients with stage I disease. Limita-
tions of minimally invasive surgical (MIS) approaches for performance 
of major thoracic procedures include two-dimensional imaging, an 
unsteady camera platform, and limited maneuverability of instruments 
used through small non-rib spreading incisions. The da Vinci® Surgi-
cal System (Intuitive Surgical®, Sunnyvale, CA) is an FDA-approved 
telerobotic system designed to address these limitations, employing the 
Insite® vision system with a true three-dimensional (3-D) endoscope 
providing a high-resolution, binocular view of the surgical ﬁeld and the 
EndoWrist® instrument system capable of seven degrees of freedom 
and two degrees of axial rotation in order to replicate human wrist-
like movements. Because there was little experience with telerobotic 
assistance for VATS lobectomy, we developed a technique for robotic 
assistance and report our experience employing the da Vinci® Surgi-
cal System. We have reviewed the indications for the procedure, the 
